Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as rNAPc2
AB201 (rNAPc2) · 2 trials · 2 indications
Proportional change is represented as percent change, and is defined as: 100 × (D-Dimer level at Day 8 or early discharge - D-Dimer level at baseline) / D-Dimer level at baseline. Baseline and post-baseline D-Dimer results are tested in the same laboratory, i.e. both from central laboratory, or local laboratory paired samples if the central laboratory values are not available.
| Arm | Type | Description |
|---|---|---|
| rNAPc2 Higher Dose | EXPERIMENTAL | loading dose of 7.5 μg/kg SC on Day 1 followed by 5 μg/kg SC on Days 3 and 5 |
| rNAPc2 Lower Dose | EXPERIMENTAL | loading dose of 5 ug/kg SC on Day 1 followed by 3 ug/kg SC on Days 3 and 5 |
| Heparin | ACTIVE_COMPARATOR | heparin at either prophylactic or therapeutic doses per Standard of Care at Institution |
| Name | Type | Description |
|---|---|---|
| rNAPc2 | DRUG | two dose levels of rNAPc2 |
| Heparin | DRUG | standard of care heparin per institution (therapeutic or prophylactic regimen) |
Inclusion Criteria: 1. Age ≥ 18 years and ≤ 90 years at the Screening assessment 2. Weight ≥ 50 kg at randomization 3. Hospitalized with a diagnosis of COVID-19 and in need of inpatient medical care 4. Positive for SARS-CoV-2 on nasopharyngeal, oropharyngeal or other tissue/body fluid samples by PC...
Top 8 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 5 | PHASE3 | Ziltivekimab |
| Novartis AG Sponsored ADR | NVS | 4 | PHASE3 | Inclisiran |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE3 | Zilebesiran |
| Viatris, Inc. | VTRS | 1 | PHASE3 | Selatogrel |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | Obicetrapib |
| GE Healthcare Technologies Inc. | GEHC | 3 | PHASE1 | Regadenoson |
| AstraZeneca PLC | AZN | 1 | - | Tezepelumab |
| Sanofi SA Sponsored ADR | SNY | 1 | - | alirocumab |
AB201, also known as rNAPc2, is an investigational drug studied for coronary disease and COVID-19. It has been evaluated in Phase 2 clinical trials, including a study of anticoagulation in patients with coronary disease and a study assessing safety, hospitalization, and efficacy in COVID-19 patients.
AB201 (rNAPc2) targets tissue factor, a protein involved in the coagulation cascade. By binding to tissue factor, the drug is designed to inhibit the coagulation process. This mechanism underlies its investigation as an anticoagulant in conditions such as coronary disease and COVID-19.
AB201 (rNAPc2) is being developed by Oruka Therapeutics, Inc., which trades under the ticker ORKA. The company is responsible for the clinical development of this investigational asset.
AB201 (rNAPc2) is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 2 trials have been completed, one in coronary disease and one in COVID-19.
AB201 (rNAPc2) has been studied in two completed Phase 2 trials. NCT04655586 evaluated safety, hospitalization, and efficacy in COVID-19 across the United States, Argentina, and Brazil. NCT00116012 assessed anticoagulation with rNAPc2 in coronary disease in the United States.
Yes, AB201 is also known as rNAPc2. Both names refer to the same investigational drug developed by Oruka Therapeutics. The alternative name rNAPc2 is often used in scientific literature and clinical trial records.